Medical device company Globus Medical (NYSE:GMED) fell short of the market’s revenue expectations in Q1 CY2025, with sales ...

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral. Analyst Price Forecast Suggests 68.61% Upside As of May 7, 2025, the average ...

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target following ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high estimate of $82.00, and a low estimate of $68.00. A negative shift in sentiment is ...

BTIG analysts have downgraded Globus Medical from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (BMV:GMED) from Buy to Neutral. There are 759 funds or institutions reporting positions in Globus Medical.

Shares of GMED opened at $58.23 on Monday. The stock has a market capitalization of $8.01 billion, a P/E ratio of 77.64, a P/E/G ratio of 1.61 and a beta of 1.32. Globus Medical has a twelve month ...

Lazard Asset Management LLC decreased its stake in Globus Medical, Inc. (NYSE:GMED – Free Report) by 14.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities ...

Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ("Globus" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...

Detailed price information for Globus Medical Inc (GMED-N) from The Globe and Mail including charting and trades.